NCT06480110View on ClinicalTrials.gov

Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 20, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2027

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

Docetaxel + Ebastine

Ebastine is administered once daily.

DRUG

Docetaxel

docetaxel every three weeks

Trial Locations (1)

2100

RECRUITING

Department of Oncology 5073, Rigshospitalet, Copenhagen

All Listed Sponsors
collaborator

Danish Cancer Society

OTHER

lead

Rigshospitalet, Denmark

OTHER